AEROLATE JR

Clinical safety rating: caution

Comprehensive clinical and safety monograph for AEROLATE JR (AEROLATE JR).

How it works

Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.

What the body does with it

Metabolism	Primarily metabolized in the liver by cytochrome P450 enzymes, including CYP1A2, CYP2E1, and CYP3A4. Metabolism is saturable at high concentrations.
Excretion	Renal elimination: 60-70% as unchanged drug and metabolites. Biliary/fecal excretion: 20-30%.
Half-life	Terminal elimination half-life: 3.5-4.5 hours. This short half-life supports twice-daily dosing in asthma management, with trough levels remaining above therapeutic threshold.
Protein binding	Approximately 70% bound to plasma proteins, primarily albumin.
Volume of Distribution	Volume of distribution: 0.3-0.5 L/kg. This moderate Vd indicates distribution into total body water and some tissue binding, but limited by protein binding.
Bioavailability	Oral bioavailability: Approximately 50% due to first-pass metabolism. Inhalation bioavailability: Variable, with 10-20% reaching systemic circulation; remainder swallowed and undergoes first-pass metabolism.
Onset of Action	Oral administration: Onset of bronchodilation occurs within 30 minutes, with peak effect at 2-4 hours.
Duration of Action	Duration of bronchodilation: 8-12 hours, allowing twice-daily dosing. Duration may be shorter in acute exacerbations or with suboptimal dosing.

Classification & Brands

Dosing & administration

1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.

Dosage form	CAPSULE, EXTENDED RELEASE
Renal impairment	No adjustment required as drug is primarily hepatically metabolized.
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
Pediatric use	Children 4-11 years: 1 inhalation (35 mcg) twice daily; children 12-17 years: same as adult.
Geriatric use	No specific dose adjustment; initiate at lower end of dosing range due to potential comorbidities.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for AEROLATE JR (AEROLATE JR).

Breastfeeding	Excreted in breast milk; M/P ratio 2.5. Use caution; may cause tremors or tachycardia in infant. Consider risk-benefit.
Teratogenic Risk	FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used near term due to beta-agonist effects; avoid for tocolysis.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

None.

Side Effect Profile

Serious Effects

Absolute Contraindications

Hypersensitivity to theophylline or any component of the formulation.

Clinical Precautions

Precautions	Concurrent illness (especially with fever), smoking cessation, drug interactions, and hepatic or cardiac impairment can significantly alter theophylline clearance. Serum levels must be monitored due to narrow therapeutic index. Use with caution in patients with peptic ulcer, seizure disorders, or hyperthyroidism.
Food/Dietary	High-fat meals may delay absorption. Charcoal-broiled foods and high-protein diets can increase clearance. Avoid concurrent consumption of large amounts of caffeine.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

AEROLATE JR

Clinical safety rating: caution

Comprehensive clinical and safety monograph for AEROLATE JR (AEROLATE JR).

How it works

What the body does with it

Metabolism	Primarily metabolized in the liver by cytochrome P450 enzymes, including CYP1A2, CYP2E1, and CYP3A4. Metabolism is saturable at high concentrations.
Excretion	Renal elimination: 60-70% as unchanged drug and metabolites. Biliary/fecal excretion: 20-30%.
Half-life	Terminal elimination half-life: 3.5-4.5 hours. This short half-life supports twice-daily dosing in asthma management, with trough levels remaining above therapeutic threshold.
Protein binding	Approximately 70% bound to plasma proteins, primarily albumin.
Volume of Distribution	Volume of distribution: 0.3-0.5 L/kg. This moderate Vd indicates distribution into total body water and some tissue binding, but limited by protein binding.
Bioavailability	Oral bioavailability: Approximately 50% due to first-pass metabolism. Inhalation bioavailability: Variable, with 10-20% reaching systemic circulation; remainder swallowed and undergoes first-pass metabolism.
Onset of Action	Oral administration: Onset of bronchodilation occurs within 30 minutes, with peak effect at 2-4 hours.
Duration of Action	Duration of bronchodilation: 8-12 hours, allowing twice-daily dosing. Duration may be shorter in acute exacerbations or with suboptimal dosing.

Classification & Brands

Dosing & administration

1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.

Dosage form	CAPSULE, EXTENDED RELEASE
Renal impairment	No adjustment required as drug is primarily hepatically metabolized.
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
Pediatric use	Children 4-11 years: 1 inhalation (35 mcg) twice daily; children 12-17 years: same as adult.
Geriatric use	No specific dose adjustment; initiate at lower end of dosing range due to potential comorbidities.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for AEROLATE JR (AEROLATE JR).

Breastfeeding	Excreted in breast milk; M/P ratio 2.5. Use caution; may cause tremors or tachycardia in infant. Consider risk-benefit.
Teratogenic Risk	FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used near term due to beta-agonist effects; avoid for tocolysis.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

None.

Side Effect Profile

Serious Effects

Absolute Contraindications

Hypersensitivity to theophylline or any component of the formulation.

Clinical Precautions

Precautions	Concurrent illness (especially with fever), smoking cessation, drug interactions, and hepatic or cardiac impairment can significantly alter theophylline clearance. Serum levels must be monitored due to narrow therapeutic index. Use with caution in patients with peptic ulcer, seizure disorders, or hyperthyroidism.
Food/Dietary	High-fat meals may delay absorption. Charcoal-broiled foods and high-protein diets can increase clearance. Avoid concurrent consumption of large amounts of caffeine.

Clinical Tips & Counseling

Drug interactions

Loading safety data…